Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
iBio, Inc. (NASDAQ:IBIO) announced it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on Tuesday, stating that the company’s common stock did not meet the minimum closing bid price requirement of $1.00 per share for the preceding 30 consecutive business days, from June 13, 2025 to July 28, 2025, as required by Nasdaq Listing Rule 5550(a)(2).
According to the filing, the notice does not immediately affect the listing or trading of iBio’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbol “IBIO.” The company has 180 calendar days, until January 26, 2026, to regain compliance. If the closing bid price of the company’s common stock is at or above $1.00 for at least 10 consecutive business days during this period, Nasdaq will notify the company that it has regained compliance.
Nasdaq may, at its discretion, require the closing bid price to meet or exceed the $1.00 requirement for more than 10 consecutive business days, but generally not more than 20 days, before determining that the company is in compliance.
If iBio does not regain compliance by January 26, 2026, it may be eligible for an additional 180 calendar days to meet the requirement, provided it meets other continued listing standards and notifies Nasdaq in writing of its intention to cure the deficiency, including potentially effecting a reverse stock split. If the company does not meet these conditions, or if Nasdaq determines that compliance cannot be achieved, the company’s common stock will be subject to delisting.
iBio stated it intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with Nasdaq listing requirements.
This information is based on a statement made in a press release and a filing with the Securities and Exchange Commission.
In other recent news, iBio Inc . announced promising preclinical data for its engineered amylin receptor agonist antibody, which reduced acute food intake by 60% in a mouse model of obesity. This development is part of iBio’s collaboration with AstralBio, focusing on selective activation of the amylin receptor. Additionally, iBio will host a conference call to discuss advancements in obesity and cardiometabolic disease treatments. CEO Martin Brenner is expected to present the company’s obesity strategy, including insights on its long-acting Myostatin antibody IBIO-600 and new preclinical data on Activin E.
Furthermore, iBio has initiated a non-human primate study for its Activin E antibody candidate IBIO-610. This study aims to evaluate the pharmacokinetics and early efficacy signals of IBIO-610 in obese and elderly non-human primates. The focus will be on fat reduction and body composition, with initial data anticipated by early fourth quarter. These developments highlight iBio’s ongoing efforts in addressing obesity and related conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.